%0 Journal Article %T Clinical and Molecular Effects of GnRH Agonist and Antagonist on The Cumulus Cells in The In Vitro Fertilization Cycle %J International Journal of Fertility and Sterility %I Royan Institute, Iranian Academic Center for Education Culture and Research (ACECR) %Z 2008-076X %A Azizollahi, Saeed %A Bagheri, Maryam %A Haghollahi, Fedyeh %A Mohamadi, Seyyede Momeneh %A Hosein Rashidi, Batool %D 2021 %\ 07/01/2021 %V 15 %N 3 %P 202-209 %! Clinical and Molecular Effects of GnRH Agonist and Antagonist on The Cumulus Cells in The In Vitro Fertilization Cycle %K Apoptosis %K Cumulus Cells %K GnRH Agonist %R 10.22074/ijfs.2020.136161.1012 %X Background: Gonadotropin-releasing hormone (GnRH) analogues have been extensively utilized in the ovarian s timulationcycle for suppression of endogenous rapid enhancement of luteinizing hormone (LH surge). Exclusive propertiesand functional mechanisms of GnRH analogues in in vitro fertilization (IVF) cycles are clearly described. This s tudy wasperformed to evaluate clinical and molecular impacts of the GnRH agonis t and antagonis t protocols in IVF cycles. Forthis purpose, gene expression of cumulus cells (CCs) as well as clinical and embryological parameters were evaluatedand compared between two groups (GnRH agonis t and antagonis t) during the IVF cycle. Materials and Methods: Twenty-one infertile individuals were enrolled in this s tudy. Subjects wereselected from two groups of GnRH agonis t (n=10) treated patients and GnRH antagonis t (n=11) treated individuals.The defined clinical embryological parameters were compared between the two groups. Expression of BAX, BCL-2,SURVIVIN, ALCAM, and VCAN genes were assessed in the CCs of the participants using the real-time polymerasechain reaction (PCR) technique. Results: The mean number of cumulus oocyte complex (COC), percentage of metaphase II (MII) oocytes, grade Aembryo and clinical parameters did not show noticeable differences between the two groups. BAX gene expression inthe CCs of the group treated with GnRH agonis t was remarkably higher than those received GnRH antagonis t treatment(P<0.001). The mRNA expression of BCL-2 and ALCM genes were considerably greater in the CCs of patientswho underwent antagonis t protocol in comparison to the group that received agonis t protocol (P<0.001). Conclusion: Despite no considerable difference in the oocyte quality, embryo development, and clinical outcomes betweenthe group treated with GnRH agonis t and the one treated with antagonis t protocol, the GnRH antagonis t protocolwas slightly more favorable. However, further clinical s tudies using molecular assessments are required to elucidatethis controversial subject. %U https://www.ijfs.ir/article_239411_852c657994edf7b7589e4bb3c6e6defe.pdf